Journals / Türk Kardiyoloji Derneği Arşivi / 2018 / Cilt: 46 - Sayı: 2

Evaluation of the association between serum uric acid level and the predicted risk score of sudden cardiac death in five years in patients with hypertrophic cardiomyopathy

Hipertrofik kardiyomiyopatili hastalarda serum ürik asit seviyesi ile öngörülen beş yıllık ani kardiyak ölüm risk skoru arasındaki ilişkinin değerlendirilmesi

Pages
111–120
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Namely, HCM Risk-SCD >6%, UA: 6.71±1.29 mg/dL, HCM Risk-SCD ≤5.9%, UA: 5.84±1.39 mg/dL, p=0.001; fQRS(+),UA: 6.56±1.20 mg/dL, fQRS(-), UA: 5.63±1.49 mg/dL, p6.320 pg/mL, UA: 6.56±1.27 mg/dL, galectin-3 ≤6.310pg/mL, p=0.016; left atrium anterior-posterior dimension (LAAPD)>36 mm, UA: 6.31±1.33 mg/dL, LAAPD

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the relationshipbetween serum uric acid (UA) level and the predicted risk score forsudden cardiac death in 5 years (the HCM Risk-SCD), galectin-3level, and positive fragmented QRS (fQRS) on electrocardiography(ECG) in patients with hypertrophic cardiomyopathy (HCM).Methods: This was a prospective, observational study.
📊
Key Findings & Data:In all, 115consecutive patients (age >17 years) with HCM and 80 healthy participants were included in the study.
💡
Conclusion & Impact:Namely, HCM Risk-SCD >6%, UA: 6.71±1.29 mg/dL, HCM Risk-SCD ≤5.9%, UA: 5.84±1.39 mg/dL, p=0.001; fQRS(+),UA: 6.56±1.20 mg/dL, fQRS(-), UA: 5.63±1.49 mg/dL, p6.320 pg/mL, UA: 6.56±1.27 mg/dL, galectin-3 ≤6.310pg/mL, p=0.016; left atrium anterior-posterior dimension (LAAPD)>36 mm, UA: 6.31±1.33 mg/dL, LAAPD
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the relationshipbetween serum uric acid (UA) level and the predicted risk score forsudden cardiac death in 5 years (the HCM Risk-SCD), galectin-3level, and positive fragmented QRS (fQRS) on electrocardiography(ECG) in patients with hypertrophic cardiomyopathy (HCM).Methods: This was a prospective, observational study. In all, 115consecutive patients (age >17 years) with HCM and 80 healthy participants were included in the study. The HCM Risk-SCD score (%),galectin-3 level, and fQRS on ECG were evaluated in all patients.Results: The serum UA, galectin-3 level, UA/Creatinine ratio, incidence of ventricular tachycardia (VT) and syncope, and someechocardiographic parameters were significantly higher in the patient group than in the control group (all p6%. Namely, HCM Risk-SCD >6%, UA: 6.71±1.29 mg/dL, HCM Risk-SCD ≤5.9%, UA: 5.84±1.39 mg/dL, p=0.001; fQRS(+),UA: 6.56±1.20 mg/dL, fQRS(-), UA: 5.63±1.49 mg/dL, p6.320 pg/mL, UA: 6.56±1.27 mg/dL, galectin-3 ≤6.310pg/mL, p=0.016; left atrium anterior-posterior dimension (LAAPD)>36 mm, UA: 6.31±1.33 mg/dL, LAAPD

Özet

Amaç: Bu çalışmanın amacı hipertrofik kardiyomiyopati (HKM) bulunan hastalarda serum ürik asit (ÜA) seviyesi ile öngörülen beş yıllık ani kardiyak ölüm riski (HKM-AKÖ) skoru (%), galektin-3 düzeyi, elektrokardiyografi’de (EKG) fragmente QRS (fQRS) pozitifliği arasında ki ilişkiyi belirlemektir. Yöntemler: Bu ileriye dönük gözlemsel bir çalışmadır. Çalışmaya, ardışık 115 HKM’li hasta ve 80 sağlıklı birey dahil edildi. Tüm hastaların HKM-AKÖ risk skoru, galektin-3 düzeyi, EKG’de fQRS varlığı değerlendirildi. Bulgular: Serum ÜA, galektin-3 düzeyi, ÜA/Kreatinin (Kr), ventriküler taşikardi (VT) and senkop sıklığı, bazı ekokardiyografi parametreleri hasta grubunda kontrol grubuna göre anlamlı derecede yüksekti (tüm p%6, ÜA: 6.71±1.29 mg/dL, HKM-AKÖ risk ≤%5.9, ÜA: 5.84±1.39 mg/dL, p=0.001; fQRS(+), ÜA: 6.56±1.20 mg/dL, fQRS(-), ÜA: 5.63±1.49 mg/dL, p6.320 pg/mL, UA: 6.56±1.27 mg/dL, galectin-3 ≤6.310 pg/mL, ÜA: 5.90±2.43 mg/dL, p=0.016, sol atriyum ön-arka çap (SAAPÇ) >36 mm, ÜA: 6.31±1.33 mg/dL, SAAPÇ

🔖

Cite This Article

SERDAR, O. A., SATILMIŞOĞLU, M. H., UYAREL, H., ÖZYILMAZ, S., GÜL, M. (2022). Evaluation of the association between serum uric acid level and the predicted risk score of sudden cardiac death in five years in patients with hypertrophic cardiomyopathy. Türk Kardiyoloji Derneği Arşivi, Cilt: 46 - Sayı: 2, 111–120. https://ajindex.com/articles/632119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79
  2. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41:987–93
  3. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014;35:2010–20. 4. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60–8
  4. Özyılmaz S, Akgül Ö, Uyarel H, Pusuroğlu H, Karayakalı M, Gül M, et al. Assessment of the association between the presence of fragmented QRS and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy. Anatol J Cardiol 2017;18:54–61
  5. Das MK, Suradi H, Maskoun W, Michael MA, Shen C, Peng J, et al. Fragmented wide QRS on a 12-lead ECG: a sign of myocardial scar and poor prognosis. Circ Arrhythm Electrophysiol 2008;1:258–68
  6. Liu T, Zhang X, Korantzopoulos P, Wang S, Li G. Uric acid levels and atrial fibrillation in hypertensive patients. Intern Med 2011;50:799–803
  7. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al; JCARE-CARD Investigators. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 2011;151:143–7
  8. Zhu L, Wang J, Wang Y, Jia L, Sun K, Wang H, et al. Plasma Uric Acid as a Prognostic Marker in Patients With Hypertrophic Cardiomyopathy. Can J Cardiol 2015;31:1252–8
  9. Pusuroglu H, Akgul O, Erturk M, Bolat I, Tasbulak O, Ornek V, et al. Assessment of relationship between galectin-3 and ambulatory ECG-based microvolt T-wave alternans in sustained systolic-diastolic hypertension patients. Blood Press Monit 2016;21:265–70
  10. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardio